Aurobindo Pharma wins USFDA nod for generic version of Mucinex Tablets
Guaifenesin extended-release tablets are the generic version of RB Health (US) LLC's Mucinex tablets, Aurobindo Pharma said.
New Delhi: Drug firm Aurobindo Pharma on Thursday said it has received the final nod from the US health regulator for its Guaifenesin extended-release tablets used as Expectorant.
The company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture its generic Guaifenesin extended-release tablets in the strengths of 600 mg and 1,200 mg, Aurobindo Pharma said in a filing to the BSE.
The product is expected to be launched in the fourth quarter of 2019-20, it added.
The company's tablets are the generic version of RB Health (US) LLC's Mucinex tablets, Aurobindo Pharma said.
Read Also: Aurobindo Pharma Unit-7 documents inaccurate, misleading: USFDA
"The approved product has an estimated market size of USD 301 million for the twelve months ending July 2019, according to IRI database," it added.
Guaifenesin extended-release tablets help to loosen phlegm, and thin bronchial secretions to rid bronchial passageways of bothersome mucus and make coughs more productive, the company said.
The company now has a total of 419 abbreviated new drug applications (ANDA) approvals (392 final approvals including 21 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA, it added.
Read Also: Aurobindo Pharma rises 5 pc post clarification on USFDA observations for Unit-7
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd